A key metabolic enzyme which keeps malaria parasites alive has been found to exist at each stage of infection in humans.
Researchers found that by targeting the enzyme PI4L using drug compounds called imidazopyrazines, they were able to kill the parasite in its dormant stage of infection.
Until now, antimalarial medications were only able to target parasites when active in the human bloodstream.
Read more at Columbia University Medical Center